Skip to content
Partners4Access
Expert global consultancy specializing in access for orphan drugs
Partners4Access
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact
Search:
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact

Category Archives: Publications/White Papers

You are here:
  1. Home
  2. Category "Publications/White Papers"

Innovative Access Agreements: A potential payer solution for Cell & Gene Therapies

Publications/White PapersBy partnersadminSeptember 21, 2018

A US and EU perspective By Daniele Severi Bruni & Sophie Schmitz What’s the idea? Payer concerns over increasing cost of therapies and uncertainty of clinical data has led to a growing interest in market access tools. Experts Daniele Severi Bruni partner at MKO and Sophie Schmitz from Partners4Access discuss this potential payer solution for…

CAR-T Therapies, the future for cancer patients? A market access perspective

Publications/White PapersBy partnersadminAugust 17, 2018

Chimeric Antigen Receptor T-cell (CAR-T) therapies, which use a patient’s own immune cells to fight cancer, are one of the most exciting breakthroughs in cancer treatment for decades. Research into this technology has been ongoing since the early 1990s, but only in the last few years have these treatments been successfully used to treat cancer…

What does the new FDA accelerated regulatory pathway mean for gene therapies?

Publications/White PapersBy partnersadminMay 23, 2018

U.S. Food and Drug Administration (FDA) commissioner Scott Gottlieb has announced that the drug agency is developing a system by which innovative gene therapies could be sped through the regulatory process. In a speech to board members of the Alliance for Regenerative Medicine, Dr. Gottlieb spoke about the challenges associated with reviewing cell and gene…

Biopharma 2018 Success Kit: 11 months to go, 6 rare disease trends to watch!

Publications/White PapersBy NickFebruary 2, 2018

For the rapidly developing orphan drug market, change is a constant. From new technologies to discussions over pricing, the estimated $137 billion market will witness new challenges for biopharma companies in the rare disease space. In a bid to unravel these barriers and with 11 months more to go in 2018, the team at Partners4Access…

ICER finds Roche’s Hemlibra cost-effective despite high price tag

Publications/White PapersBy NickFebruary 1, 2018

Roche’s new haemophilia treatment, Hemlibra, is has a high estimated price tag of $482,000 for the first year of treatment and $448,000 for every subsequent year. Despite this, an analysis by the U.S. Institute for Clinical and Economic Review (ICER) has revealed that the treatment is still cost effective. The report stated that the Hemlibra…

Sanofi to buy Bioverativ in $11.6 billion deal

Publications/White PapersBy NickJanuary 25, 2018

French pharmaceutical giant Sanofi have agreed to acquire Bioverativ, a U.S. hemophilia specialist for $11.6 billion. This deal is the biggest for Sanofi in seven years, with the aim of achieving a stronger position in the rare disease space. After initially falling due to investor speculation that Bioverativ was overvalued, shares in Sanofi have since…

UK regulator attempts to ease fears of impending access abyss

Publications/White PapersBy NickJanuary 18, 2018

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) announced that there would be no sudden changes to the UK regulatory framework in the event of a no-deal following Brexit negotiations. It went on to confirm that it would provide “adequate notice to industry and ensure that companies had sufficient time to implement any changed…

Generation Bio pioneers revolutionary gene therapy delivery system

Publications/White PapersBy NickJanuary 11, 2018

The biotech venture capital firm Atlas Ventures has announced the creation of Generation Bio, a company that has developed a system by which the dosage of a gene therapy can be varied to maximise the potential benefit. The company has started on the back of a $25 million Series A funding round from Atlas. The…

Spark Therapeutics Announces $850 000 price tag of gene therapy treatment Luxturna

Publications/White PapersBy NickJanuary 4, 2018

Spark Therapeutics has announced its recently approved Luxturna (voretigene neparvovec-rzyl), a gene therapy treatment for biallelic RPE65 mutation-associated retinal dystrophy will cost $425 000 per eye, or $850 000 in total, in the U.S. This is below the $1 million price tag that was originally speculated. Spark Therapeutics is also working with Harvard Pilgrim, a…

FDA approves gene therapy for rare form of vision loss

Publications/White PapersBy NickDecember 21, 2017

The U.S. Food and Drug Administration (FDA) has approved the use of Spark Therapeutics’ gene therapy Luxturna (voretigene neparvovec-rzyl) for the treatment of a rare inherited form of vision loss and blindness. This marks the first approval by the FDA of a directly administered gene therapy for the treatment of a disease caused by mutations…

123
TwitterInstagramLinkedin

All Rights Reserved © Privacy Partners 4 Access 2020

Go to Top